In a patient with disparate MMR pelvic primaries (locally advanced dMMR endometrial cancer and locally advanced pMMR rectal cancer), how would you approach treatment management?

If the patient received 3 cycles carbo/taxol/pembro, how would you approach further treatment for the following: 1. Given that that patient wants to pursue a non-operative approach for the pMMR rectal cancer to avoid a permanent colostomy, how would you approach local control for the Stage IIIC endometrial cancer after pelvic radiation? 2. Following NRG-GI002 data and GY018/KEYNOTE-868 in a discordant MMR dual-primary cancer patient, would you continue maintenance pembrolizumab post-radiation?